Plasma Concentration and Clinical Effect in Imipramine Treatment of Childhood Enuresis

Jørgensen, Ole Sylvester; Lober, Marianne; Christiansen, Jan; Gram, Lars F.

doi:10.2165/00003088-198005040-00006

Cited by 47 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further study is required for clarification of the mechanisms and the magnitude of the alterations observed since it cannot be clearly established from the data collected here. Moreover the scarce number of similar studies, and the discrepancies found among them, make it difficult for us to compare our results with others (Jorgensen et al, 1980;Kolvin et al, 1973;Meadow, 1974). Besides, the variables chosen and the methodology used in each study are different.…”

Section: Discussionmentioning

confidence: 72%

The influence of clinical and pharmacological factors on enuresis treatment with imipramine.

Gatta

Galindo-Villardón

Rey

et al. 1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. The aim of this study has been to evaluate the response to imipramine treatment in enuretic children through the use of a series of clinical and pharmacological variables and by applying a multivariate (principal components) analysis technique. 2. The study was carried out on 146 children whose ages ranged from 5 to 14 years, and who received variable doses of imipramine (12.5 to 100 mg day‐1). 3. The quantitative variables analyzed were: drug dosage, serum levels of imipramine and its metabolite desipramine, the relationship between them both, the duration of treatment, age and weight. 4. The qualitative variables were: compliance, presence of side‐effects, enuretic and/or psychiatric antecedents, intelligence quotient (I.Q.), the existence (or absence) of related pathologies, sex, and the type of enuresis. 5. The response to treatment was quantified by means of the percentage of decrease in frequency of enuresis as compared with the initial frequency. 6. The results obtained show that the variables which are most associated with the reduction of enuresis are, in decreasing order: the dosage of imipramine administered, the duration of treatment, compliance and the level/dose ratio for the sum of the drug and metabolite levels.

show abstract

Section: Discussionmentioning

confidence: 72%

The influence of clinical and pharmacological factors on enuresis treatment with imipramine.

Gatta

Galindo-Villardón

Rey

et al. 1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Kales et al [18] reported that the enuretic effects of imipramine appear to be independent of its effects on sleep stage. The clinical response has been shown to correlate with plasma levels [19]. Imipramine undergoes significant first-pass metabolism through the liver and so the bioavailability varies by about 29-77% [20,21].…”

Section: Discussionmentioning

confidence: 99%

Combination Therapy of Imipramine with Oxybutynin in Children with Enuresis Nocturna

Tahmaz

Kïbar²,

Yıldırım³

et al. 2000

Urol Int

View full text Add to dashboard Cite

Purpose: The treatment approach for enuresis is controversial due to the lack of consensus as to the exact causes of nocturnal enuresis. Despite various treatment modalities, pharmacotherapy still appears to be the common choice. The aim of this prospective study was the evaluation of the efficacy of combination therapy (imipramine and oxybutynin) in patients with enuresis nocturna. Patients and Methods: This prospective study was done with 77 monosymptomatic nocturnal enuretics between July 1996 and December 1998. Results: Even though there is no statistically significant difference between combination therapy (imipramine plus oxybutynin) and monotherapy, clinical data showed that combination therapy is more effective. Conclusions: We conclude that combination of imipramine with oxybutynin is a safe and new choice in the treatment of nocturnal enuresis.

show abstract

“…Essentially, the available data for IMI in paediatric populations are the elimination half-life (tl/2), mean serum levels, drug/metabolite ratio (IMI/DMI), leveb/dose (L/D) ratio and interindividual variability [6,[21][22][23], they all have evident limitations in the establishment of dosage schedules that will guarantee safe and efficient drug levels throughout treatment. The results found there for these parameters (h/2 = 16.3 h, IMI/DMI = 0.99) are in agreement with those reported by others.…”

Section: Discussionmentioning

confidence: 99%

Population pharmacokinetics of imipramine in children

Tamayo

Gatta

García

et al. 1992

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The population pharmacokinetics of imipramine (IMI) and its active metabolite desipramine (DMI) have been evaluated using 177 IMI and DMI serum levels from 49 enuretic children (6-13 y) on IMI treatment. Standard two stage (STS) and maximum likelihood (ML) methods were used to estimate fixed and random effect parameters of IMI. Simultaneous estimation of the drug and metabolite parameters was carried out by the STS method. The mean value of the elimination constant of the drug and metabolite were 0.0425 h-1 and 0.0359, h-1 respectively. Significantly higher variability was found in the pharmacokinetic parameters of the metabolite. According to these estimated pharmacokinetic parameters, the recommended dose for enuretic children should be 1.7 mg.kg-1.day-1. The population pharmacokinetic parameters obtained in the study permit dosage individualisation using a bayesian algorithm.

show abstract

Plasma Concentration and Clinical Effect in Imipramine Treatment of Childhood Enuresis

Cited by 47 publications

References 9 publications

The influence of clinical and pharmacological factors on enuresis treatment with imipramine.

The influence of clinical and pharmacological factors on enuresis treatment with imipramine.

Combination Therapy of Imipramine with Oxybutynin in Children with Enuresis Nocturna

Population pharmacokinetics of imipramine in children

Contact Info

Product

Resources

About